Neurocrine Biosciences, Inc. (NBIX)

NASDAQ: NBIX · Real-Time Price · USD

128.63

-1.47 (-1.13%)

At close: Feb 20, 2026, 4:00 PM EST

128.76

+0.13 (0.10%)

After-hours: Feb 20, 2026, 6:19 PM EST

Neurocrine Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	478.6	341.3	249.7	154.5	89.6
Depreciation & Amortization	30.1	27.1	21.3	15.6	10.9
Other Amortization	-	-	-	-	17.3
Asset Writedown & Restructuring Costs	0.7	14	-	-	-
Loss (Gain) From Sale of Investments	-8.7	10.9	-46.7	-27.1	-13.5
Stock-Based Compensation	217.9	195.5	194.3	173.1	134.2
Other Operating Activities	192.9	25.8	-56.9	90.7	1.3
Change in Accounts Receivable	-210.5	-39.8	-89.3	-162.2	-28.4
Change in Inventory	-15.3	-19.1	5.4	-2.6	-2.5
Change in Accounts Payable	160.2	43.4	49	114.6	56.8
Change in Income Taxes	-18.8	50.3	91.6	-	-
Change in Other Net Operating Assets	-44.4	-54	-28.5	-17.2	-9.2
Operating Cash Flow	782.7	595.4	389.9	339.4	256.5
Operating Cash Flow Growth	31.46%	52.71%	14.88%	32.32%	12.25%
Capital Expenditures	-34	-38.2	-28.3	-16.5	-23.4
Cash Acquisitions	-	-	-	-42.7	-
Investment in Securities	-230.4	-88.6	-438.8	-117.9	-106.8
Investing Cash Flow	-264.4	-126.8	-467.1	-177.1	-130.2
Long-Term Debt Repaid	-	-308.8	-	-279	-0.1
Net Debt Issued (Repaid)	-	-308.8	-	-279	-0.1
Issuance of Common Stock	129.4	122.1	65.3	44.7	27.5
Repurchase of Common Stock	-167.7	-300	-	-	-
Financing Cash Flow	-38.3	-486.7	65.3	-234.3	27.4
Foreign Exchange Rate Adjustments	-	-	0.3	-1.3	-
Net Cash Flow	480	-18.1	-11.6	-73.3	153.7
Free Cash Flow	748.7	557.2	361.6	322.9	233.1
Free Cash Flow Growth	34.37%	54.09%	11.98%	38.52%	7.12%
Free Cash Flow Margin	26.17%	23.66%	19.16%	21.69%	20.57%
Free Cash Flow Per Share	7.30	5.37	3.58	3.27	2.38
Cash Interest Paid	-	1.6	3.8	6.6	8.6
Cash Income Tax Paid	81.4	217.5	51.5	14.4	5.1
Levered Free Cash Flow	397.81	507.33	439.25	247.63	265.75
Unlevered Free Cash Flow	397.81	507.33	439.25	247.63	264.58
Change in Working Capital	-128.8	-19.2	28.2	-67.4	16.7

Updated Feb 11, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q